MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Viemed Healthcare Cost of Revenue 2011-2026 | VMD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Viemed Healthcare
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 M | 91.1 M | 70.2 M | 54.2 M | 43.7 M | 51.2 M | 24.2 M | 16.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 115 M | 16.7 M | 58.3 M |
Quarterly Cost of Revenue Viemed Healthcare
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.6 M | 26.3 M | 25.8 M | - | 23.6 M | 22.1 M | 20.8 M | - | 18.8 M | 17.2 M | 15.6 M | - | 14.1 M | 12.9 M | 12.5 M | - | 10.9 M | 9.77 M | 10.7 M | - | 14 M | 16.9 M | 8.25 M | - | 6.32 M | 5.69 M | 5.04 M | 4.84 M | 4.1 M | 4.18 M | 3.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 M | 3.56 M | 13.8 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
1.2 B | $ 184.69 | 2.23 % | $ 13.8 B |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 34.46 | 2.96 % | $ 1.59 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.77 | 3.65 % | $ 1.73 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 292.23 | 1.41 % | $ 8.24 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.37 | 1.35 % | $ 126 M |  France |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 39.9 | 2.18 % | $ 5.94 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 63.82 | 1.01 % | $ 94.5 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.59 | 0.67 % | $ 36.7 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 10.38 | 3.7 % | $ 294 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
14 M | $ 25.21 | 1.47 % | $ 213 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.98 | -2.46 % | $ 1.2 M | USA |
 |
Inogen
INGN
|
194 M | $ 6.34 | -1.71 % | $ 169 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 94.94 | 2.11 % | $ 12.8 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.86 | 5.37 % | $ 419 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.44 | 3.74 % | $ 940 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 6.04 | 2.03 % | $ 72.2 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.88 | 4.11 % | $ 390 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 56.83 | 3.48 % | $ 1.67 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 39.73 | 3.3 % | $ 1.23 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 64.99 | 0.63 % | $ 3.55 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.63 | 1.03 % | $ 3.08 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 78.2 | 0.1 % | $ 45.7 B | USA |
 |
Myomo
MYO
|
14 M | $ 0.79 | 8.49 % | $ 33.1 M | USA |